950504-37-7

Basic information

• Product Name: (3-{2R-[2-hydroxy-2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethylamino]-ethyl}-benzyl)-(1R-methoxymethyl-2-methyl-propyl)-carbamic acid tert-butyl ester
• Synonyms: (3-{2R-[2-hydroxy-2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethylamino]-ethyl}-benzyl)-(1R-methoxymethyl-2-methyl-propyl)-carbamic acid tert-butyl ester
• CAS NO: 950504-37-7
• Molecular Weight: 559.727
• Mol File: 950504-37-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (3-{2R-[2-hydroxy-2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethylamino]-ethyl}-benzyl)-(1R-methoxymethyl-2-methyl-propyl)-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3-{2R-[2-hydroxy-2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethylamino]-ethyl}-benzyl)-(1R-methoxymethyl-2-methyl-propyl)-carbamic acid tert-butyl ester(950504-37-7)
• EPA Substance Registry System: (3-{2R-[2-hydroxy-2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethylamino]-ethyl}-benzyl)-(1R-methoxymethyl-2-methyl-propyl)-carbamic acid tert-butyl ester(950504-37-7)

Safety Data

• Hazardous Substances Data: 950504-37-7(Hazardous Substances Data)

Upstream product

• 950504-31-1 (1R-methoxymethyl-2-methyl-propyl)-{3-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-benzyl}-amine 
• 950504-33-3 [3-(2-hydroxy-ethyl)-benzyl]-(1R-methoxymethyl-2-methyl-propyl)-carbamic acid tert-butyl ester 
• 175458-86-3 (R)-1-methoxymethyl-2-methyl-propylamine hydrochloride 
• 896114-79-7 3-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-benzaldehyde 
• 167020-11-3 N-TERT-BUTOXYCARBONYL-O-METHYL-D-VALINOL 
• 167254-69-5 O-METHYL-D-VALINOL 
• 950504-35-5 (1R-methoxymethyl-2-methyl-propyl)-[3-(2-oxo-ethyl)-benzyl]-carbamic acid tert-butyl ester 
• 950504-39-9 7-[(1R)-2-amino-1-hydroxyethyl]-4-hydroxy-1,3-benzothiazol-2(3H)-one acetate 

Relevant articles and documents

BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS

The present invention relates to compounds according to formula (I) , a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.